{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010208","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.048606+00:00","generated_at":"2026-06-04T15:49:42.471958+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Calidi's FY2023 loss widens to $29.2M; cash only $1.9M; capital raise needed for key trials","bullets":["Net loss for FY2023 was $29.2M ($1.73 per share) vs $25.4M ($2.99 per share) in FY2022.","Cash and restricted cash totaled $2.1M at Dec 31, 2023, up from $0.6M a year prior but still low.","Q4 R&D expenses rose to $4.0M (from $2.3M) and G&A to $5.9M (from $2.4M) year-over-year.","City of Hope received $5.3M CIRM grant for CLD-101 ovarian cancer study; RTNova platform announced.","Interim Phase 1 data for CLD-101 expected 2Q 2024 'assuming we are successful in raising additional capital.'"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010208","json":"https://secwatch.observer/filing/0001493152-24-010208.json","markdown":"https://secwatch.observer/filing/0001493152-24-010208.md","text":"https://secwatch.observer/filing/0001493152-24-010208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:49:42.471958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21fc049f75166ae628170ca5e30183f9d2192a15","claim":"Calidi Biotherapeutics, Inc. reported financial results for fourth quarter and full fiscal year ended December 31, 2023.","evidence_excerpt":"On March 15, 2024, Calidi Biotherapeutics, Inc. (the \"Company\") issued a press release setting forth certain financial and operational information for its fourth fiscal quarter and full fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b98a21e3916ac55231b22dd48c74f9519cb1ef96","claim":"Calidi Biotherapeutics, Inc. reported three months ended December 31, 2023 results: net income net loss of $8.2 million, or $0.23 per share, EPS $0.23 per share.","evidence_excerpt":"The company reported a net loss of $8.2 million, or $0.23 per share, for the three months ended December 31, 2023, compared to a net loss of $7.8 million, or $0.90 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Net income","value":"net loss of $8.2 million, or $0.23 per share"},{"label":"EPS","value":"$0.23 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c3b6ebdd4237512d24cbc0aad3351fb22153a22b","claim":"Calidi Biotherapeutics, Inc. reported year ended December 31, 2023 results: net income net loss of $29.2 million, or $1.73 per share, EPS $1.73 per share.","evidence_excerpt":"The company reported a net loss of $29.2 million, or $1.73 per share, for the year ended December 31, 2023, compared to a net loss of $25.4 million, or $2.99 per share, for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Net income","value":"net loss of $29.2 million, or $1.73 per share"},{"label":"EPS","value":"$1.73 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}